Sun Pharma-Organon deal: Outlook is mixed
Summary
Sun Pharma's acquisition of Organon doubles its footprint but presents significant growth and debt challenges ahead.
Description
Sun Pharma's acquisition of Organon doubles its footprint but presents significant growth and debt challenges ahead.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source